MDM2 and neuroblastoma: Taken together, MDM2 dysregulation in NB and the role of MYC family proteins in high risk disease has led us to hypothesize that targeting both the MDM2 and MYC family pathways simultaneously may result in a synergistic increase in cytotoxicity in NB models, and present a possible novel therapeutic option.